NIAGARA FALLS, N.Y. — Cabbacis (OTCQB: CABI), a U.S. federally licensed tobacco product manufacturer focused on its patented harm-reduction innovations under the iBlend™ brand, has secured a significant new patent from the United States Patent and Trademark Office for its novel vaporizer pods for electronic oral vaporizers. This development further solidifies Cabbacis’s intellectual property portfolio in the rapidly evolving reduced-harm tobacco product sector.
U.S. Patent No. 12,527,346, with an expiration date of January 1, 2039, encompasses seven claims covering vaporizer pods designed for electronic vaporizers. The patent specifically details pods that incorporate blends of reconstituted tobacco and reconstituted hemp, with cannabigerolic acid (CBGA) identified as the most abundant cannabinoid in these formulations. This innovative approach utilizes reconstituted tobacco, a common component in closed-end electronic vaporizer pods, often seen in popular heated tobacco products such as IQOS®, Ploom®, and glo®.
The vaporizer pods protected by the new patent are engineered to deliver distinct and appealing taste and sensory profiles to consumers, differentiating them from existing market offerings that exclusively feature tobacco. The inclusion of hemp, which has been legally recognized nationwide in the United States since the 2018 Farm Bill, offers a non-intoxicating component, containing no more than 0.3% THC. Cabbacis is leveraging hemp strains with even lower THC concentrations to meet regulatory and product development requirements.
This latest patent adds to Cabbacis’s existing intellectual property, which includes three previously granted U.S. patents (10,777,091, 10,973,255, and 12,349,724) for vaporizer pods containing tobacco and hemp blends. The company also holds various international patents for its vaporizer pod technology. Furthermore, Cabbacis possesses U.S. patents for cigarettes utilizing blends of very-low-nicotine tobacco and hemp. The company’s innovative products are patented across numerous major global tobacco markets, including the United States, China, Europe, Brazil, Japan, and South Korea, indicating a strategic focus on widespread market penetration.
Joseph Pandolfino, Chief Executive Officer of Cabbacis, expressed his satisfaction with the new patent, stating, “We are pleased to announce this new U.S. patent for vaporizer pods, which further fortifies our already robust intellectual property position. This patent, when taken in tandem with our existing patents, comprehensively covers, across more than 30 countries, vaporizer pods comprising blends of conventional-nicotine tobacco and hemp or very-low-nicotine tobacco and hemp, and/or very-low-nicotine cigarettes comprising blends of very-low-nicotine tobacco and hemp.”
About Cabbacis
Cabbacis (OTCQB: CABI) is dedicated to commercializing patented, groundbreaking harm-reduction tobacco products tailored for the world’s approximately one billion smokers. The company’s primary offerings include its iBlend™ very-low-nicotine cigarettes and developing vaporizer pods, positioning it advantageously in anticipation of the proposed U.S. Food and Drug Administration (FDA) regulations to limit nicotine content in all U.S. cigarettes. The iBlend™ line primarily features very-low-nicotine tobacco blended with non-intoxicating hemp, designed to help users reduce their smoking or vaping consumption, transition to less harmful alternatives, and increase quit attempts. Cabbacis also intends to introduce very-low-nicotine tobacco cigarettes and little cigars without hemp, as well as vaporizer pods containing conventional-nicotine tobacco and hemp.
A recent clinical trial conducted by Cabbacis demonstrated that its very-low-nicotine cigarettes were highly rated by participants for satisfaction and significantly reduced cravings for their usual brand of cigarettes. Cabbacis holds a global patent portfolio comprising 36 issued patents and numerous pending applications, with a primary focus on tobacco-hemp combinations in cigarettes and vaporizer pods. These patents cover key markets where approximately two-thirds of the world’s smokers reside, including the United States, Europe, China, India, Japan, Indonesia, Russia, South Korea, Canada, Australia, New Zealand, Mexico, and Brazil.
For further information, visit cabbacis.com or follow the company on LinkedIn or X.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, as defined by federal securities laws. Any statements made in this document that are not statements of historical or current fact are considered forward-looking. Forward-looking statements can be identified by the use of words such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “foresee,” “intend,” “likely,” “may,” “objective,” “potential,” “plan,” “predict,” “project,” “seek,” “should,” “will,” and similar expressions, including their negative forms. Forward-looking statements reflect current expectations and are inherently subject to uncertainty. Actual outcomes or results may differ materially due to various factors. The company outlines these potential risks in the “Risk Factors” section of its Regulation A Offering Circular, qualified by the SEC on November 24, 2025, and in its Annual Report on Form 1-K for the period ended December 31, 2024, filed with the SEC. Cabbacis assumes no obligation to publicly update or revise any forward-looking statement, except as required by law.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/16385.html
